Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome

Overview

Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.

Full Title of Study: “Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2023

Arms, Groups and Cohorts

  • 20 patients with DRESS syndrome
  • 20 patients with drug induced MPE with eosinophilia
    • patients with drug induced maculopapular exanthema (MPE) with eosinophilia
  • 20 patients with drug induced MPE without eosinophilia
  • 20 Healthy subjects

Clinical Trial Outcome Measures

Primary Measures

  • Activation status of circulating eosinophils by flow cytometry
    • Time Frame: Baseline

Secondary Measures

  • Mean fluorescence intensity of CCR3 and IL-5R markers
    • Time Frame: Baseline
  • Percentage of Th2 polarized T cells
    • Time Frame: Baseline
  • Percentage of ILC2
    • Time Frame: Baseline
  • Serum levels (ELISA) of inflammatory markers
    • Time Frame: Baseline
  • Correlation between the number of activated circulating eosinophils, area degranulation and severity of DRESS
    • Time Frame: Baseline
  • Density of extracellular granules (degranulation area and number / mm2) on skin biopsies
    • Time Frame: Baseline
  • NGS analysis of rearrangements of TCR (T cell receptor)
    • Time Frame: Baseline and 3 months

Participating in This Clinical Trial

Inclusion Criteria

Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:

  • Cutaneous rash occurring at least 24 hours and at most 2 months after continuous medication use – Fever over 38 degre celcius – At least one organ dysfunction among: – Lymphadenopathy – hepatitis – Pulmonary involvement – Cardiac involvement: myocarditis, pericarditis – Renal impairment – At least one of the following hematological anomalies: – Eosinophilia ≥ 500 / mm3 . – RegiSCAR Score ≥ 4 Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia). – Adult with drug-induced rash – Without clinical criteria of severity defined by Djien among : – An evolution of more than 21 days – with organ damage as defined in group 1 Group 2 (MPE without eosinophilia): blood eosinophils < 500 / mm3 Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3 Exclusion Criteria:

  • Other cause of eosinophilia including cancer, blood disease before the introduction of suspected molecule(s). – On going oral or local corticosteroid therapy, anti-leukotriene therapy (MONTELUKAST) by the month preceding the study; – Anti-IgE therapy (OMALIZUMAB, LIGELIZUMAB), anti-IL-5 therapy (MEPOLIZUMAB, BENRALIZUMAB) or anti-IL4 and / or anti-IL13 therapy (DUPILUMAB, TRALOKINUMAB) in the 6 months preceding the study. – Any pregnant or lactating woman. – Contraindication related to the blood volume taken for the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Lille
  • Collaborator
    • Société de Dermatologie Française
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Delphine Staumont-Salle, MD,PhD, Principal Investigator, University Hospital, Lille
  • Overall Contact(s)
    • Delphine Staumont-Salle, MD,PhD, 0320444193, delphine.salle@chru-lille.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.